## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251231T120912 | Bullish | Relevance: 100%
- Lee Johnson Capital Management LLC has acquired a new stake of 22,606 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $2.51 million, as disclosed in its latest 13F filing. This investment comes as Gilead reported strong Q3 results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $131.68, despite recent insider share sales.

**2. Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs**
- Source: Insider Monkey | 20251230T174200 | Bullish | Relevance: 100%
- Gilead Sciences, Inc. (NASDAQ:GILD) has announced a three-year agreement with the US government to lower drug costs for Americans, aligning with President Trump's pricing strategy. This initiative emphasizes US-based innovation and affordability and complements Gilead's partnership with the US Department of State to provide HIV prevention medicine at no profit in affected countries. The company also plans to invest $32 billion in US manufacturing, R&D, and infrastructure, expecting significant economic value and job creation.

**3. Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026**
- Source: Yahoo Finance Singapore | 20251231T170751 | Bullish | Relevance: 100%
- Morgan Stanley raised its price target on Gilead Sciences (GILD) to $151 from $147, maintaining an Overweight rating, as biopharma policy uncertainties are expected to diminish. The firm anticipates a shift in market focus back to the industry's fundamentals. Gilead also announced positive Phase 3 clinical trial results for a new HIV-1 treatment, reinforcing its commitment to HIV innovation and providing a foundation for future regulatory submissions.

**4. Los Angeles Capital Management LLC Purchases 1,223,895 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251231T130821 | Bullish | Relevance: 100%
- Los Angeles Capital Management LLC significantly increased its stake in Gilead Sciences, Inc. by 46.7%, acquiring an additional 1,223,895 shares and now holding 3,845,379 shares valued at approximately $426.8 million. Other major institutional investors like Vanguard, Geode Capital, Norges Bank, UBS, and Invesco also boosted or established new positions in Gilead, leading to institutional ownership of 83.67%. Despite strong Q3 earnings and positive analyst ratings, company insiders have sold 136,257 shares totaling $16.9 million over the past 90 days.

**5. Ascent Group LLC Buys 11,926 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251231T084814 | Somewhat-Bullish | Relevance: 100%
- Ascent Group LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.2%, acquiring an additional 11,926 shares, bringing its total holdings to 61,250 shares valued at $6,799,000. Other institutional investors also adjusted their positions in the biopharmaceutical company. Meanwhile, company insiders, including CFO Andrew D. Dickinson and Director Jeffrey Bluestone, sold a significant number of shares, indicating a decrease in their direct ownership.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $151 | $147 | +3% |
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($10.00M) |
| Sells | 13 ($5.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.23 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $152.3B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.23 |
| Forward P/E | 14.0 |
| Current P/E | 15.0 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.2% to -0.4% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). RSI neutral at 49. OFD pattern: -STL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.44% (CS: 48) | Neutral |
| RSI_14 | 49.0 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.079x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $122.74
- **Stop Loss:** $117.66 (4.1% risk)
- **Target:** $127.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 283
- **Position Value:** $34,735.42
- **Portfolio %:** 34.74%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*